11 results
424B5
STSA
Satsuma Pharmaceuticals Inc
3 Nov 22
Prospectus supplement for primary offering
4:42pm
in the fourth quarter of 2022. If successful, we plan to submit a NDA for STS101 in the first quarter of 2023.
Migraine is a chronic and debilitating
S-3
STSA
Satsuma Pharmaceuticals Inc
23 Oct 20
Shelf registration
4:48pm
months of treatment.
Migraine is a chronic and debilitating neurological disorder characterized by attacks of often severe headache and accompanying
10-K
2019 FY
STSA
Satsuma Pharmaceuticals Inc
10 Mar 20
Annual report
4:20pm
efficacy trial of STS101 and expect to report topline data in the second half of 2020.
Migraine is a chronic and debilitating neurological disorder … trials and consider additional headache indications for STS101 to maximize its commercial potential.
Migraine Overview
Migraine is a chronic
424B4
9uxfphg
13 Sep 19
Prospectus supplement with pricing info
5:08pm
S-1/A
3i3rkp93
3 Sep 19
IPO registration (amended)
6:12am
S-1
a5i9 vykd
16 Aug 19
IPO registration
5:15pm
DRS/A
7gqd2jtgemt0kgi
2 Aug 19
Draft registration statement (amended)
12:00am
DRS
57w7kn6toiewwp9t
21 Jun 19
Draft registration statement
12:00am
- Prev
- 1
- Next